Vries-Sluijs, T.E.M.S. de

patient hbsag hepatitis vaccination response level count study schedule baseline hbsag seroclearance hbeag-negative patients decline hbeag-positive patients hepatitis b treatment group hbeag-positive seroclearance haart rotterdam hbeag therapy hbsag level hbeag-negative analysis erasmus university rotterdam ef ficacy population signi erasmu virus antigen tenofovir disoproxil fumarate hepatitis b vaccination erasmus universiteit rotterdam vaccine hiv /hbv patients fi rst year hiv-infected patients result signi ficantly kinetic month figure 6 years hiv-infected university department surface center hbeag loss tdf therapy anti-hb hiv-rna effect compliance baseline hbsag level downloaded difference hepatitis b vaccine pinteraction serum hospital hiv-rna load cells /mm antiretroviral therapy ficacy disease tenofovir hbsag kinetics hbsag levels gilead sciences hbv vaccination hbv dna level immunode ficiency virus vaccination schedule 3 vaccinations erasmus mc hbeag-positive population